229 related articles for article (PubMed ID: 33453650)
1. Lassa-VSV chimeric virus targets and destroys human and mouse ovarian cancer by direct oncolytic action and by initiating an anti-tumor response.
van den Pol AN; Zhang X; Lima E; Pitruzzello M; Albayrak N; Alvero A; Davis JN; Mor G
Virology; 2021 Mar; 555():44-55. PubMed ID: 33453650
[TBL] [Abstract][Full Text] [Related]
2. Lassa-vesicular stomatitis chimeric virus safely destroys brain tumors.
Wollmann G; Drokhlyansky E; Davis JN; Cepko C; van den Pol AN
J Virol; 2015 Jul; 89(13):6711-24. PubMed ID: 25878115
[TBL] [Abstract][Full Text] [Related]
3. Natural killer T cell immunotherapy combined with oncolytic vesicular stomatitis virus or reovirus treatments differentially increases survival in mouse models of ovarian and breast cancer metastasis.
Gebremeskel S; Nelson A; Walker B; Oliphant T; Lobert L; Mahoney D; Johnston B
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33722907
[TBL] [Abstract][Full Text] [Related]
4. Chikungunya, Influenza, Nipah, and Semliki Forest Chimeric Viruses with Vesicular Stomatitis Virus: Actions in the Brain.
van den Pol AN; Mao G; Chattopadhyay A; Rose JK; Davis JN
J Virol; 2017 Mar; 91(6):. PubMed ID: 28077641
[TBL] [Abstract][Full Text] [Related]
5. A recombinant vesicular stomatitis virus-based Lassa fever vaccine protects guinea pigs and macaques against challenge with geographically and genetically distinct Lassa viruses.
Safronetz D; Mire C; Rosenke K; Feldmann F; Haddock E; Geisbert T; Feldmann H
PLoS Negl Trop Dis; 2015 Apr; 9(4):e0003736. PubMed ID: 25884628
[TBL] [Abstract][Full Text] [Related]
6. Explicit targeting of transformed cells by VSV in ovarian epithelial tumor-bearing Wv mouse models.
Capo-chichi CD; Yeasky TM; Heiber JF; Wang Y; Barber GN; Xu XX
Gynecol Oncol; 2010 Feb; 116(2):269-75. PubMed ID: 19932656
[TBL] [Abstract][Full Text] [Related]
7. Vesicular stomatitis virus has extensive oncolytic activity against human sarcomas: rare resistance is overcome by blocking interferon pathways.
Paglino JC; van den Pol AN
J Virol; 2011 Sep; 85(18):9346-58. PubMed ID: 21734048
[TBL] [Abstract][Full Text] [Related]
8. Vesiculovirus neutralization by natural IgM and complement.
Tesfay MZ; Ammayappan A; Federspiel MJ; Barber GN; Stojdl D; Peng KW; Russell SJ
J Virol; 2014 Jun; 88(11):6148-57. PubMed ID: 24648451
[TBL] [Abstract][Full Text] [Related]
9. Immune Effects of M51R Vesicular Stomatitis Virus Treatment of Carcinomatosis From Colon Cancer.
Day GL; Bryan ML; Northrup SA; Lyles DS; Westcott MM; Stewart JH
J Surg Res; 2020 Jan; 245():127-135. PubMed ID: 31415934
[TBL] [Abstract][Full Text] [Related]
10. Retargeting Oncolytic Vesicular Stomatitis Virus to Human T-Cell Lymphotropic Virus Type 1-Associated Adult T-Cell Leukemia.
Betancourt D; Ramos JC; Barber GN
J Virol; 2015 Dec; 89(23):11786-800. PubMed ID: 26378177
[TBL] [Abstract][Full Text] [Related]
11. The lytic activity of VSV-GP treatment dominates the therapeutic effects in a syngeneic model of lung cancer.
Schreiber LM; Urbiola C; Das K; Spiesschaert B; Kimpel J; Heinemann F; Stierstorfer B; Müller P; Petersson M; Erlmann P; von Laer D; Wollmann G
Br J Cancer; 2019 Oct; 121(8):647-658. PubMed ID: 31530903
[TBL] [Abstract][Full Text] [Related]
12. Chikungunya-vesicular stomatitis chimeric virus targets and eliminates brain tumors.
Zhang X; Mao G; van den Pol AN
Virology; 2018 Sep; 522():244-259. PubMed ID: 30055515
[TBL] [Abstract][Full Text] [Related]
13. Mucin-Like Domain of Ebola Virus Glycoprotein Enhances Selective Oncolytic Actions against Brain Tumors.
Zhang X; Zhang T; Davis JN; Marzi A; Marchese AM; Robek MD; van den Pol AN
J Virol; 2020 Mar; 94(8):. PubMed ID: 32051271
[TBL] [Abstract][Full Text] [Related]
14. Oncolytic efficacy of recombinant vesicular stomatitis virus and myxoma virus in experimental models of rhabdoid tumors.
Wu Y; Lun X; Zhou H; Wang L; Sun B; Bell JC; Barrett JW; McFadden G; Biegel JA; Senger DL; Forsyth PA
Clin Cancer Res; 2008 Feb; 14(4):1218-27. PubMed ID: 18281557
[TBL] [Abstract][Full Text] [Related]
15. Vesicular stomatitis virus expressing tumor suppressor p53 is a highly attenuated, potent oncolytic agent.
Heiber JF; Barber GN
J Virol; 2011 Oct; 85(20):10440-50. PubMed ID: 21813611
[TBL] [Abstract][Full Text] [Related]
16. Changes in Susceptibility to Oncolytic Vesicular Stomatitis Virus during Progression of Prostate Cancer.
Yu N; Puckett S; Antinozzi PA; Cramer SD; Lyles DS
J Virol; 2015 May; 89(10):5250-63. PubMed ID: 25741004
[TBL] [Abstract][Full Text] [Related]
17. Oncolytic vesicular stomatitis virus administered by isolated limb perfusion suppresses osteosarcoma growth.
Kubo T; Shimose S; Matsuo T; Fujimori J; Sakaguchi T; Yamaki M; Shinozaki K; Woo SL; Ochi M
J Orthop Res; 2011 May; 29(5):795-800. PubMed ID: 21437961
[TBL] [Abstract][Full Text] [Related]
18. Potential of vesicular stomatitis virus as an oncolytic therapy for recurrent and drug-resistant ovarian cancer.
Heiber JF; Xu XX; Barber GN
Chin J Cancer; 2011 Dec; 30(12):805-14. PubMed ID: 22059911
[TBL] [Abstract][Full Text] [Related]
19. A Novel Chimeric Oncolytic Virus Vector for Improved Safety and Efficacy as a Platform for the Treatment of Hepatocellular Carcinoma.
Abdullahi S; Jäkel M; Behrend SJ; Steiger K; Topping G; Krabbe T; Colombo A; Sandig V; Schiergens TS; Thasler WE; Werner J; Lichtenthaler SF; Schmid RM; Ebert O; Altomonte J
J Virol; 2018 Dec; 92(23):. PubMed ID: 30232179
[TBL] [Abstract][Full Text] [Related]
20. Vesicular stomatitis virus as an oncolytic agent against pancreatic ductal adenocarcinoma.
Murphy AM; Besmer DM; Moerdyk-Schauwecker M; Moestl N; Ornelles DA; Mukherjee P; Grdzelishvili VZ
J Virol; 2012 Mar; 86(6):3073-87. PubMed ID: 22238308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]